Literature DB >> 21514245

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

Rafael B Blasco1, Sarah Francoz, David Santamaría, Marta Cañamero, Pierre Dubus, Jean Charron, Manuela Baccarini, Mariano Barbacid.   

Abstract

We have investigated the role of individual members of the Raf/Mek/Erk cascade in the onset of K-Ras oncogene-driven non-small cell lung carcinoma (NSCLC). Ablation of Erk1 or Erk2 in K-Ras oncogene-expressing lung cells had no significant effect due to compensatory activities. Yet, elimination of both Erk kinases completely blocked tumor development. Similar results were obtained with Mek kinases. Ablation of B-Raf had no significant effect on tumor development. However, c-Raf expression was absolutely essential for the onset of NSCLC. Interestingly, concomitant elimination of c-Raf and B-Raf in adult mice had no deleterious consequences for normal homeostasis. These results indicate that c-Raf plays a unique role in mediating K-Ras signaling and makes it a suitable target for therapeutic intervention.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514245      PMCID: PMC4854330          DOI: 10.1016/j.ccr.2011.04.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  51 in total

1.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors:  Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

2.  Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.

Authors:  Surbhi Gupta; Antoine R Ramjaun; Paula Haiko; Yihua Wang; Patricia H Warne; Barbara Nicke; Emma Nye; Gordon Stamp; Kari Alitalo; Julian Downward
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

3.  In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.

Authors:  Nicolas Dumaz; Robert Hayward; Jan Martin; Lesley Ogilvie; Douglas Hedley; John A Curtin; Boris C Bastian; Caroline Springer; Richard Marais
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

4.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

5.  Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice.

Authors:  G Pagès; S Guérin; D Grall; F Bonino; A Smith; F Anjuere; P Auberger; J Pouysségur
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

6.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

Authors:  John Rinehart; Alex A Adjei; Patricia M Lorusso; David Waterhouse; J Randolph Hecht; Ronald B Natale; Oday Hamid; Mary Varterasian; Peggy Asbury; Eric P Kaldjian; Stephen Gulyas; David Y Mitchell; Roman Herrera; Judith S Sebolt-Leopold; Mark B Meyer
Journal:  J Clin Oncol       Date:  2004-10-13       Impact factor: 44.544

Review 7.  Role of Rho-family proteins in cell adhesion and cancer.

Authors:  Angeliki Malliri; John G Collard
Journal:  Curr Opin Cell Biol       Date:  2003-10       Impact factor: 8.382

8.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Authors:  James Tsai; John T Lee; Weiru Wang; Jiazhong Zhang; Hanna Cho; Shumeye Mamo; Ryan Bremer; Sam Gillette; Jun Kong; Nikolas K Haass; Katrin Sproesser; Ling Li; Keiran S M Smalley; Daniel Fong; Yong-Liang Zhu; Adhirai Marimuthu; Hoa Nguyen; Billy Lam; Jennifer Liu; Ivana Cheung; Julie Rice; Yoshihisa Suzuki; Catherine Luu; Calvin Settachatgul; Rafe Shellooe; John Cantwell; Sung-Hou Kim; Joseph Schlessinger; Kam Y J Zhang; Brian L West; Ben Powell; Gaston Habets; Chao Zhang; Prabha N Ibrahim; Peter Hirth; Dean R Artis; Meenhard Herlyn; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis.

Authors:  Osamu Yamaguchi; Tetsuya Watanabe; Kazuhiko Nishida; Kazunori Kashiwase; Yoshiharu Higuchi; Toshihiro Takeda; Shungo Hikoso; Shinichi Hirotani; Michio Asahi; Masayuki Taniike; Atsuko Nakai; Ikuko Tsujimoto; Yasushi Matsumura; Jun-ichi Miyazaki; Kenneth R Chien; Atsushi Matsuzawa; Chiharu Sadamitsu; Hidenori Ichijo; Manuela Baccarini; Masatsugu Hori; Kinya Otsu
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

10.  RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein.

Authors:  David Matallanas; David Romano; Karen Yee; Katrin Meissl; Lucia Kucerova; Daniela Piazzolla; Manuela Baccarini; J Keith Vass; Walter Kolch; Eric O'neill
Journal:  Mol Cell       Date:  2007-09-21       Impact factor: 17.970

View more
  132 in total

Review 1.  Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Authors:  Matthias Drosten; Carmen Guerra; Mariano Barbacid
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

2.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

3.  Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG¹²D/Pdx-1-Cre Mice.

Authors:  Jie Liao; Sung Hee Hwang; Haonan Li; Jun-Yan Liu; Bruce D Hammock; Guang-Yu Yang
Journal:  Anticancer Res       Date:  2016-01       Impact factor: 2.480

4.  New insight puts CRAF in sight as a therapeutic target.

Authors:  Ana Paula Rebocho; Richard Marais
Journal:  Cancer Discov       Date:  2011-07       Impact factor: 39.397

5.  A systems biology approach to personalizing therapeutic combinations.

Authors:  Lawrence N Kwong; Timothy P Heffernan; Lynda Chin
Journal:  Cancer Discov       Date:  2013-12       Impact factor: 39.397

6.  The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.

Authors:  Edward B Garon; Richard S Finn; Habib Hamidi; Judy Dering; Sharon Pitts; Naeimeh Kamranpour; Amrita J Desai; Wylie Hosmer; Susan Ide; Emin Avsar; Michael Rugaard Jensen; Cornelia Quadt; Manway Liu; Steven M Dubinett; Dennis J Slamon
Journal:  Mol Cancer Ther       Date:  2013-03-14       Impact factor: 6.261

7.  MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.

Authors:  Chih-Shia Lee; Liam C Lee; Tina L Yuan; Sirisha Chakka; Christof Fellmann; Scott W Lowe; Natasha J Caplen; Frank McCormick; Ji Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-01       Impact factor: 11.205

8.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Authors:  Weiying Zhang; Nivedita Nandakumar; Yuhao Shi; Mark Manzano; Alias Smith; Garrett Graham; Swati Gupta; Eveline E Vietsch; Sean Z Laughlin; Mandheer Wadhwa; Mahandranauth Chetram; Mrinmayi Joshi; Fen Wang; Bhaskar Kallakury; Jeffrey Toretsky; Anton Wellstein; Chunling Yi
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192

Review 9.  Circulating tumor cells and CDX models as a tool for preclinical drug development.

Authors:  Alice Lallo; Maximilian W Schenk; Kristopher K Frese; Fiona Blackhall; Caroline Dive
Journal:  Transl Lung Cancer Res       Date:  2017-08

10.  TPL2 kinase is a suppressor of lung carcinogenesis.

Authors:  Katerina Gkirtzimanaki; Kalliopi K Gkouskou; Urszula Oleksiewicz; Georgios Nikolaidis; Dimitra Vyrla; Michalis Liontos; Vassiliki Pelekanou; Dimitris C Kanellis; Kostantinos Evangelou; Efstathios N Stathopoulos; John K Field; Philip N Tsichlis; Vassilis Gorgoulis; Triantafillos Liloglou; Aristides G Eliopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.